-       Report 
- October 2025
-  477 Pages 
- Global 
   From       €5206EUR$5,850USD£4,582GBP 
          -       Report 
- June 2025
-  400 Pages 
- Global 
   From       €4404EUR$4,949USD£3,877GBP 
            -       Report 
- September 2025
-  83 Pages 
- Global 
   From       €3500EUR$4,213USD£3,189GBP 
          -       Report 
- July 2025
-  112 Pages 
- Global 
   From       €3500EUR$4,213USD£3,189GBP 
          -       Report 
- July 2025
-  85 Pages 
- Global 
   From       €3500EUR$4,213USD£3,189GBP 
           -       Report 
- May 2025
-  99 Pages 
- Global 
   From       €3500EUR$4,213USD£3,189GBP 
          -       Report 
- March 2025
-  79 Pages 
- Global 
   From       €3500EUR$4,213USD£3,189GBP 
            -       Report 
- August 2025
-  150 Pages 
- Global 
   From       €2988EUR$3,358USD£2,630GBP 
      €3515EUR$3,950USD£3,094GBP 
            -       Report 
- August 2025
-  150 Pages 
- Global 
   From       €2988EUR$3,358USD£2,630GBP 
      €3515EUR$3,950USD£3,094GBP 
            -       Training 
- December 2025
-  2 Days 
- Global 
        €1527EUR$1,776USD£1,299GBP 
      €1762EUR$2,050USD£1,499GBP 
          -       Report 
- January 2025
-  182 Pages 
- Global 
   From       €4445EUR$4,995USD£3,913GBP 
          -       Report 
- January 2025
-  209 Pages 
- Global 
   From       €4445EUR$4,995USD£3,913GBP 
          -       Report 
- August 2025
-  200 Pages 
- United States 
   From       €2216EUR$2,490USD£1,950GBP 
          -       Report 
- July 2025
-  250 Pages 
- Asia Pacific 
   From       €3443EUR$3,869USD£3,031GBP 
          -       Report 
- June 2025
-  300 Pages 
- Latin America 
   From       €3443EUR$3,869USD£3,031GBP 
          -       Report 
- June 2025
-  90 Pages 
- United States 
   From       €4316EUR$4,850USD£3,799GBP 
            -       Report 
- January 2025
-  230 Pages 
- United States 
   From       €2492EUR$2,800USD£2,193GBP 
      €3115EUR$3,500USD£2,742GBP 
          -       Report 
- March 2020
-  137 Pages 
- Global 
   From       €4359EUR$4,899USD£3,837GBP 
          -       Report 
- November 2023
-  215 Pages 
- Global 
   From       €4644EUR$5,402USD£3,950GBP 
          -       Report 
- February 2024
-  202 Pages 
- Global 
   From       €4449EUR$5,000USD£3,917GBP 
       
      The RNA Vaccine market is a subset of the larger Vaccine market, which is composed of products designed to prevent and treat infectious diseases. RNA Vaccines are a relatively new type of vaccine, which use genetic material to stimulate an immune response. This type of vaccine is particularly attractive due to its potential to be quickly developed and manufactured, as well as its ability to target a wide range of diseases.
RNA Vaccines are being developed for a variety of diseases, including    influenza, malaria, and cancer. These vaccines are being studied in clinical trials, and some have already been approved for use in humans.
The RNA Vaccine market is expected to grow in the coming years, as more vaccines are developed and approved. This growth is driven by the increasing demand for vaccines, as well as the potential for RNA Vaccines to be used to treat a wide range of diseases.
Some companies in the RNA Vaccine market include Moderna, Inovio Pharmaceuticals, CureVac, and Arcturus Therapeutics. Show Less   Read more